-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bayer announced that its promyocyopin receptor kinase (TRK) inhibitor VITRAKVI (larotrectinib) was recommended by the National Institute for Health and Clinical Optimization (NICE) to treat neurotrophic tyrosine receptor kinase therapy (NTRK) gene fusion-positive locallate, metastatic or surgical lying that may cause serious health problems, and there are no other satisfactory treatment options for adults and pediatric patients with solid tumorsLarotrectinib is an oral TRK inhibitor that can be used to treat solid tumors with NTRK gene fusion, regardless of the source of the primary tumorNICE's decision is based on Phase I clinical trials in adult patients, Phase II NAVIGATE trials in adult and adolescent patients, and I/II childhood SCOUT trialsThe results of Larotrectinib showed a aggregate total clinical response rate (ORR) of 67% in adult and pediatric patients with NTRK gene fusion-positive solid tumorsIn people who did not include primary central nervous system tumors, THE ORR was 72%Amanda Cunnington,Bayer UK, said: 'Bayer is proud to work with NICE and NHS England throughout the assessment process to provide a new oral treatment for cancer patients integrated by NTRK'